NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
Clinical Trials
11 trialsNCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT04644289 2025-10-03
WoO
AGO Research GmbH
Phase 2 Recruiting
NCT06121401 2025-09-17
IOLANTHE
Mario Negri Institute for Pharmacological Research
Phase 4 Active not recruiting
NCT05700669 2024-09-19
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
Valerio Therapeutics
Phase 1/2 Completed
NCT04377087 2024-08-20
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Terminated
NCT03106987 2022-10-07
OReO
AstraZeneca
Phase 3 Completed
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT02822157 2021-01-29
CLIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown